These results suggest that NPM1-mutant AML with low FLT3-ITD allelic ratios is not a favorable risk factor, and patients with this mutation type require more treatment modalities such as a combination of FLT3 inhibitors in addition to conventional induction and consolidation chemotherapies proceeding allogeneic HCT. The gene discussed is NPM1; the disease is acute myeloid leukemia.